Literature DB >> 29054361

Metastatic melanoma imaging using a novel Tc-99m-labeled lactam-cyclized alpha-MSH peptide.

Liqin Liu1, Jingli Xu2, Jianquan Yang2, Changjian Feng3, Yubin Miao4.   

Abstract

The purpose of this study was to determine the metastatic melanoma imaging property of 99mTc(EDDA)-HYNIC-Aoc-Nle-CycMSHhex {hydrazinonicotinamide-8-aminooctanoic acid-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-CONH2}. HYNIC-Aoc-Nle-CycMSHhex was synthesized using fluorenylmethyloxy carbonyl (Fmoc) chemistry. The IC50 value of HYNIC-Aoc-Nle-CycMSHhex was 0.78 ± 0.13 nM for B16/F10 melanoma cells. 99mTc(EDDA)-HYNIC-Aoc-Nle-CycMSHhex displayed significantly higher uptake (14.26 ± 2.74 and 10.45 ± 2.31% ID/g) in B16/F10 metastatic melanoma-bearing lung than that in normal lung (0.90 ± 0.15 and 0.53 ± 0.14% ID/g) at 2 and 4 h post-injection, respectively. B16/F10 pulmonary metastatic melanoma lesions were clearly visualized by SPECT/CT using 99mTc(EDDA)-HYNIC-Aoc-Nle-CycMSHhex as an imaging probe at 2 h post-injection, underscoring its potential as an imaging probe for metastatic melanoma detection.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (99m)Tc-labeled lactam-cyclized peptide; Alpha-melanocyte stimulating hormone; Metastatic melanoma imaging

Mesh：

Substances：

Year:  2017        PMID： 29054361      PMCID： PMC5667642          DOI： 10.1016/j.bmcl.2017.10.022

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  23 in total

1.  Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents.

Authors:  J B Tatro; S Reichlin
Journal:  Endocrinology       Date:  1987-11       Impact factor: 4.736

2.  Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues.

Authors:  J Chen; Z Cheng; T J Hoffman; S S Jurisson; T P Quinn
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

3.  Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells.

Authors:  W Siegrist; F Solca; S Stutz; L Giuffrè; S Carrel; J Girard; A N Eberle
Journal:  Cancer Res       Date:  1989-11-15       Impact factor: 12.701

4.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

5.  A (99m)Tc(CO)(3)-labeled pyrazolyl-alpha-melanocyte-stimulating hormone analog conjugate for melanoma targeting.

Authors:  Paula D Raposinho; João D G Correia; Susana Alves; Maria F Botelho; Ana C Santos; Isabel Santos
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

6.  Phase I/II study of ipilimumab for patients with metastatic melanoma.

Authors:  Jeffrey S Weber; Steven O'Day; Walter Urba; John Powderly; Geoff Nichol; Michael Yellin; Jolie Snively; Evan Hersh
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

7.  Novel, cysteine-modified chelation strategy for the incorporation of [M(I)(CO)(3)](+) (M = Re, (99m)Tc) in an α-MSH peptide.

Authors:  Han Jiang; Benjamin B Kasten; Hongguang Liu; Shibo Qi; Yang Liu; Mei Tian; Charles L Barnes; Hong Zhang; Zhen Cheng; Paul D Benny
Journal:  Bioconjug Chem       Date:  2012-11-08       Impact factor: 4.774

8.  In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy.

Authors:  Yubin Miao; Nellie K Owen; Donna Whitener; Fabio Gallazzi; Timothy J Hoffman; Thomas P Quinn
Journal:  Int J Cancer       Date:  2002-10-10       Impact factor: 7.396

9.  Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties.

Authors:  Paula D Raposinho; Catarina Xavier; João D G Correia; Soraia Falcão; Paula Gomes; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2008-01-08       Impact factor: 3.358

10.  Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues.

Authors:  Yubin Miao; Donna Whitener; Weiwei Feng; Nellie K Owen; Jianqing Chen; Thomas P Quinn
Journal:  Bioconjug Chem       Date:  2003 Nov-Dec       Impact factor: 4.774
View more
  3 in total

1.  68Ga-DOTA-GGNle-CycMSHhex targets the melanocortin-1 receptor for melanoma imaging.

Authors:  Jianquan Yang; Jingli Xu; Rene Gonzalez; Thomas Lindner; Clemens Kratochwil; Yubin Miao
Journal:  Sci Transl Med       Date:  2018-11-07       Impact factor: 17.956

2.  PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma.

Authors:  Emily Howard; Benjamin P Hurrell; Doumet Georges Helou; Christine Quach; Jacob D Painter; Pedram Shafiei-Jahani; Marshall Fung; Parkash S Gill; Pejman Soroosh; Arlene H Sharpe; Omid Akbari
Journal:  Front Immunol       Date:  2021-08-31       Impact factor: 8.786

3.  The Value of Technetium-99m Labeled Alpha-Melanocyte-Stimulating Hormone (99mTc-α-MSH) in Diagnosis of Primary and Metastatic Lesions of Malignant Melanoma.

Authors:  Saeed Farzanefar; Rahman Etemadi; Mohammad Shirkhoda; Habibollah Mahmoodzadeh; Mostafa Erfani; Babak Fallahi; Mehrshad Abbasi; Narjess Ayati; Arman Hassanzadeh-Rad; Mohammad Eftekhari; Davood Beiki
Journal:  Asia Ocean J Nucl Med Biol       Date:  2018
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.